Market Cap 7.69B
Revenue (ttm) 675.04M
Net Income (ttm) 141.21M
EPS (ttm) N/A
PE Ratio 65.18
Forward PE 69.15
Profit Margin 20.92%
Debt to Equity Ratio 0.00
Volume 456,300
Avg Vol 874,824
Day's Range N/A - N/A
Shares Out 105.37M
Stochastic %K 28%
Beta 0.46
Analysts Strong Sell
Price Target $135.25

Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also develop...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 327 3270
Address:
101 Redwood Shores Parkway, Redwood City, United States
Jdogg85
Jdogg85 Oct. 24 at 6:57 PM
$CORT only closes red on days ending in Y
1 · Reply
druvaciam
druvaciam Oct. 24 at 6:32 PM
$CORT Probably the only stock that is down today lol
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 24 at 3:12 PM
$CORD $CORT Cycle Trading Signal plugged into AI 🔥 list 10/10/25 results
0 · Reply
Jdogg85
Jdogg85 Oct. 24 at 2:45 PM
$CORT all these analysts have 140+ SP targets yet this can barely hold 73, what gives?
1 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 24 at 12:09 PM
Hey you! $CONI $COOK $CORD $CORT Keep counting Math don't lie 🔥 Cycle Trading Signal plugged into AI 🔥 lists accuracy
0 · Reply
gucag006
gucag006 Oct. 24 at 4:21 AM
$CORT Nothing changed except that we're inching closer to Relacorilant's PDUFA date of 12/30/25 (for Cushing Syndrome). Don't forget the SP was around $40 a year ago, and $20 two years ago. The shorties have been here as long as I can remember, but our (longs) financial prospects were swapped with the shorties - we're seeing inflating balance sheets while they're sinking into the money abyss with no bottom in sight.
0 · Reply
druvaciam
druvaciam Oct. 23 at 1:59 PM
$CORT Falls every single day. How is it possible that no one want to buy?
2 · Reply
stewpackard
stewpackard Oct. 23 at 9:38 AM
$CORT this executive team sucks, stock is down almost 20 bucks the past two weeks and these aholes havent addressed shareholders on the distributor issue AT ALL
2 · Reply
voorbie
voorbie Oct. 21 at 7:39 PM
I always dread $CORT earnings. It seems like no matter what - even when they beat expectations - the stock price goes down.
2 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Oct. 21 at 12:56 PM
$CORT nearly 90% of the company is owned by tutes
3 · Reply
Latest News on CORT
Corcept Transition To New Specialty Pharmacy Well Underway

Oct 15, 2025, 9:13 AM EDT - 10 days ago

Corcept Transition To New Specialty Pharmacy Well Underway


Corcept Primed For An Upside EPS Surprise

Sep 26, 2025, 12:06 PM EDT - 4 weeks ago

Corcept Primed For An Upside EPS Surprise


Jdogg85
Jdogg85 Oct. 24 at 6:57 PM
$CORT only closes red on days ending in Y
1 · Reply
druvaciam
druvaciam Oct. 24 at 6:32 PM
$CORT Probably the only stock that is down today lol
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 24 at 3:12 PM
$CORD $CORT Cycle Trading Signal plugged into AI 🔥 list 10/10/25 results
0 · Reply
Jdogg85
Jdogg85 Oct. 24 at 2:45 PM
$CORT all these analysts have 140+ SP targets yet this can barely hold 73, what gives?
1 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 24 at 12:09 PM
Hey you! $CONI $COOK $CORD $CORT Keep counting Math don't lie 🔥 Cycle Trading Signal plugged into AI 🔥 lists accuracy
0 · Reply
gucag006
gucag006 Oct. 24 at 4:21 AM
$CORT Nothing changed except that we're inching closer to Relacorilant's PDUFA date of 12/30/25 (for Cushing Syndrome). Don't forget the SP was around $40 a year ago, and $20 two years ago. The shorties have been here as long as I can remember, but our (longs) financial prospects were swapped with the shorties - we're seeing inflating balance sheets while they're sinking into the money abyss with no bottom in sight.
0 · Reply
druvaciam
druvaciam Oct. 23 at 1:59 PM
$CORT Falls every single day. How is it possible that no one want to buy?
2 · Reply
stewpackard
stewpackard Oct. 23 at 9:38 AM
$CORT this executive team sucks, stock is down almost 20 bucks the past two weeks and these aholes havent addressed shareholders on the distributor issue AT ALL
2 · Reply
voorbie
voorbie Oct. 21 at 7:39 PM
I always dread $CORT earnings. It seems like no matter what - even when they beat expectations - the stock price goes down.
2 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Oct. 21 at 12:56 PM
$CORT nearly 90% of the company is owned by tutes
3 · Reply
JarvisFlow
JarvisFlow Oct. 20 at 2:02 PM
HC Wainwright & Co. has updated their rating for Corcept Therapeutics ( $CORT ) to Buy with a price target of 145.
1 · Reply
StocktwitsNews
StocktwitsNews Oct. 20 at 9:40 AM
Corcept Therapeutics Stock Slips Premarket Despite Strong Cancer Trial Data Showing 40% Drop In Disease Progression Risk $CORT https://stocktwits.com/news/equity/markets/corcept-therapeutics-stock-slips-premarket-despite-strong-cancer-trial-data-showing-40-drop-in-disease-progression-risk/ch6CoMYR3Y7
1 · Reply
gucag006
gucag006 Oct. 20 at 5:35 AM
$CORT (Relacorilant) for Cushing's syndrome, common side effects include: Back pain Headache Peripheral edema (swelling in the hands, feet, and ankles) Nausea and abdominal pain Pain in the extremities Diarrhea Dizziness Serious side effects were rare in these trials. Importantly, studies showed that relacorilant did not cause the unintended hormonal side effects associated with some other cortisol blockers, such as: Vaginal bleeding or endometrial thickening Potassium deficiency (hypokalemia) Excessive cortisol receptor antagonism or adrenal insufficiency
0 · Reply
gucag006
gucag006 Oct. 20 at 5:31 AM
$CORT To be fair, the following are taken from Recorlev () official site: Recorlev BOXED WARNING: HEPATOTOXICITY AND QT PROLONGATION HEPATOTOXICITY Cases of hepatotoxicity with fatal outcome or requiring liver transplantation have been reported with oral ketoconazole. Some patients had no obvious risk factors for liver disease. Recorlev is associated with serious hepatotoxicity. Evaluate liver enzymes prior to and during treatment. QT PROLONGATION Recorlev is associated with dose-related QT interval prolongation. QT interval prolongation may result in life-threatening ventricular dysrhythmias such as torsades de pointes. Perform ECG and correct hypokalemia and hypomagnesemia prior to and during treatment. To be continued....
0 · Reply
Silent_Raven6450
Silent_Raven6450 Oct. 19 at 11:34 PM
$CORT Perfect bounce off support, averaging down here
0 · Reply
AcrossMarkets
AcrossMarkets Oct. 19 at 11:29 PM
$CORT is getting serious attention — NASDAQ listed, biotech sector, and primed for a potential surge with relacorilant data in platinum-resistant ovarian cancer. 🔍 Are you #bullish or #bearish on CORT right now? Read the full blog: https://www.acrossmarkets.icu/2025/10/corcept-therapeutics-charts-new-path-in.html
0 · Reply
Bubbarayjr62
Bubbarayjr62 Oct. 19 at 10:56 PM
$CORT Officer. “With the FDA's recent acceptance of our New Drug Application for relacorilant in platinum- resistant ovarian cancer and the expansion of our BELLA trial, we are closer than ever to bringing new and vital treatment to patients in need. We are grateful to all the patients and investigators for participating in our ongoing trials.” Corcept previously announced that ROSELLA met its primary endpoint of improved PFS, with no need for biomarker selection. Patients who received relacorilant in addition to nab-paclitaxel chemotherapy experienced a 30 percent reduction in the risk of disease progression compared to patients who received nab-paclitaxel monotherapy (hazard ratio: 0.70; p-value: 0.0076). An interim analysis of overall survival (OS) showed that the addition of relacorilant reduced the risk of death by 31 percent, substantially lengthening patients’ lives (hazard ratio: 0.69; p-value: 0.0121).
1 · Reply
Bubbarayjr62
Bubbarayjr62 Oct. 19 at 10:56 PM
$CORT necessitate further research of relacorilant and its potential benefit in earlier treatment lines of gynecological cancers.” Corcept also announced the expansion of the recently initiated Phase 2 BELLA trial to three study arms to evaluate the efficacy and safety of: (i) relacorilant plus nab-paclitaxel and bevacizumab to treat patients with platinum-resistant ovarian cancer; (ii) relacorilant plus nab-paclitaxel and bevacizumab to treat patients with platinum-sensitive ovarian cancer whose disease progressed while on a PARPi and (iii) relacorilant plus nab-paclitaxel to treat patients with endometrial cancer who had received one or two prior lines of therapy. Initial results are expected in late 2026. “The ROSELLA data give us confidence to expand the BELLA trial to include patients with ovarian cancer whose disease is platinum sensitive (an earlier stage of tumor progression), as well as patients with endometrial cancer,” said Bill Guyer, PharmD, Corcept’s Chief Development
0 · Reply
Bubbarayjr62
Bubbarayjr62 Oct. 19 at 10:55 PM
$CORT for both subgroups. Relacorilant plus nab-paclitaxel was well-tolerated in the PARPi subgroups, consistent with its known safety profile. Importantly, the type, frequency and severity of adverse events in the combination arms were comparable to those in the nab-paclitaxel monotherapy arms. Relacorilant conferred its benefit without increasing the safety burden of the patients who received it. “These new ROSELLA data substantiate the significant benefit of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer, an extremely difficult-to-treat cancer,” said Domenica Lorusso, M.D., Ph.D., Director of the Gynaecological Oncology Unit at Humanitas Hospital San Pio X, Milan, and Full Professor of Obstetrics and Gynaecology, Humanitas University, Rozzano, European Network of Gynaecological Oncological Trial groups Principal Investigator in the ROSELLA trial and ESMO presenter. “These findings are especially promising for patients with an exceptionally poor prognosis and
0 · Reply
Bubbarayjr62
Bubbarayjr62 Oct. 19 at 10:55 PM
$CORT today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here. New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relacorilant plus nab-paclitaxel showed a PFS benefit in patients with prior PARPi treatment (hazard ratio: 0.60; p-value: 0.0035) and in patients whose disease progressed while on a PARPi (hazard ratio: 0.56; p-value: 0.0046), with a median PFS of 7.36 months
0 · Reply
Bubbarayjr62
Bubbarayjr62 Oct. 19 at 10:54 PM
$CORT Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment • New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis • Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer REDWOOD CITY, Calif., (October 19, 2025) — Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol,
0 · Reply
TheAlmani
TheAlmani Oct. 19 at 5:59 PM
$CORT This means investor optimism at least. I will keep holding.
0 · Reply